These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients. Boston Center for Liver Transplantation Cytomegalovirus Immune Globulin Study Group. Falagas ME; Snydman DR; Ruthazer R; Werner BG; Griffith J Clin Infect Dis; 1997 May; 24(5):824-9. PubMed ID: 9142776 [TBL] [Abstract][Full Text] [Related]
11. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. Goodrich JM; Mori M; Gleaves CA; Du Mond C; Cays M; Ebeling DF; Buhles WC; DeArmond B; Meyers JD N Engl J Med; 1991 Dec; 325(23):1601-7. PubMed ID: 1658652 [TBL] [Abstract][Full Text] [Related]
12. The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Abecassis MM; Koffron AJ; Kaplan B; Buckingham M; Muldoon JP; Cribbins AJ; Kaufman DB; Fryer JP; Stuart J; Stuart FP Transplantation; 1997 Jan; 63(2):275-9. PubMed ID: 9020330 [TBL] [Abstract][Full Text] [Related]
13. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease. Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309 [TBL] [Abstract][Full Text] [Related]
16. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050 [TBL] [Abstract][Full Text] [Related]
17. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523 [TBL] [Abstract][Full Text] [Related]
18. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744 [TBL] [Abstract][Full Text] [Related]
19. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients. Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314 [TBL] [Abstract][Full Text] [Related]
20. Management and prevention of cytomegalovirus infection after renal transplantation. Farrugia E; Schwab TR Mayo Clin Proc; 1992 Sep; 67(9):879-90. PubMed ID: 1331630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]